Relay Medical and Glow LifeTech report on successful phase II clinical results for COVID-19 treatment

Relay Medical and Glow LifeTech report on successful phase II clinical results for COVID-19 treatment
Share this article


TORONTO – Relay Medical Corp. (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, and Glow LifeTech Ltd. a private company in which Relay holds a significant equity interest, today reported on developments related to Glow’s MyCell Technology™.

Glow LifeTech partner Swiss Pharmacan AG, and MGC Pharma have announced the full results of Phase II double-blind, placebo-controlled clinical trial for anti-inflammatory treatment ArtemiC™, powered by MyCell Technology™, on persons diagnosed with COVID-19, has successfully met all the Phase II primary and secondary endpoints and demonstrated to improve the clinical recovery of COVID-19 patients.

MGC has completed its phase II randomized controlled clinical trial on ArtemiC™ involving 50 patients and the results show ArtemiC™ statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group. The results deliver a full safety and efficacy profile, demonstrating to improve and expedite the clinical recovery in moderate COVID-19 patients, with no drug-related adverse events. None of the patients supported by ArtemiC™ required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance.

ArtemiC™ is a natural anti-inflammatory formulation by MGC Pharma, which is powered by Mycell Technology™, the same delivery system technology that Glow LifeTech has the exclusive North American license to manufacture, sell and market for cannabis and certain nutraceutical ingredients. The natural formulation, jointly developed by Glow partner Swiss PharmaCan, is based on four MyCell™ enhanced ingredients: Artemisinin, Curcumin, Vitamin c, and Boswellia Serrata, which are well-known natural active ingredients with anti-inflammatory properties. The formulation is intended to suppress the cytokine storm and clinical deterioration to support the recovery of COVID-19 patients. Glow LifeTech owns the exclusive rights for the sale, manufacturing and distribution of MyCell™ curcumin in the United States, Canada and Mexico.

“These are very exciting results for Glow’s MyCell Technology™ and the ArtemiC™ formulation. We are pleased that our innovative MyCell Technology™ is helping to power a natural formulation that shows promising ability to improve and expedite the recovery of COVID-19 patients. It demonstrates the long term potential of MyCell Technology™ to power next generation natural health products with science-backed efficacy and safety,” said Clark Kent, Chief Executive Officer, Glow LifeTech.

MGC completed its trial on ArtemiC™ on 50 COVID-19 infected patients across 3 independent hospital sites in Israel. The Trial met all the FDA requirements for a COVID-19 study. These results now open potential market opportunities for ArtemiC™ to a wide range of diseases related to cytokine storm such as influenza, autoimmune diseases, inflammatory GI diseases and chemotherapy patients.

Following the successful Phase II results, MGC plans to develop and commence a Phase III clinical trial in the first half of 2021. The Phase III trial is anticipated to be an international multicentre study to encompass a wide range of inflammatory indications for the use of ArtemiC™ as a treatment.

“Relay and Glow are critical partners of ours in commercializing MyCell Technology™ in North America and beyond. We look forward to building on our relationship as we roll-out breakthrough innovations like ArtemiC™. With Glow preparing to list on the CSE, they will positioned well to support our mission of bringing innovative health products to the market,” said Michel Fässler, Managing Director, Swiss PharmaCan AG.

On November 25, 2020 Glow Lifetech announced that it had received conditional approval to list its common shares on the Canadian Securities Exchange pursuant to an amalgamation transaction with Ateba Resources Inc. Glow’s conditional approval to list its common shares on the CSE is subject to the completion of a financing raise of an additional $2.5 million and the completion of the amalgamation with Ateba.

Glow and Swiss PharmaCan have initiate a regulatory assessment to determine the best path forward for the commercialization of ArtemiC in North America.

Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and AI data science sectors.


We seek Safe Harbor.

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.